{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:24:30Z","timestamp":1770740670011,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12880-016-0139-7","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T04:44:34Z","timestamp":1462423474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn\u2019s disease: correlation with SES-CD and clinical-biological markers"],"prefix":"10.1186","volume":"16","author":[{"given":"Luca Pio","family":"Stoppino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Della Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Cleopazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Centola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatello","family":"Iamele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Bristogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Stoppino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Macarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"139_CR1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641\u201357.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"139_CR2","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","volume":"55","author":"SP Travis","year":"2006","unstructured":"Travis SP, Stange EF, Lemann M, et al. European Crohn\u2019s and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management. Gut. 2006;55 Suppl 1:i16\u201335.","journal-title":"Gut"},{"key":"139_CR3","first-page":"821","volume":"371","author":"E Breese","year":"1995","unstructured":"Breese E, McDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995;371:821\u20134.","journal-title":"Adv Exp Med Biol"},{"key":"139_CR4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593\u2013610.","journal-title":"Gastroenterology"},{"key":"139_CR5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","volume":"133","author":"M Clark","year":"2007","unstructured":"Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, june 21\u201323, 2006. Gastroenterology. 2007;133:312\u201339.","journal-title":"Gastroenterology"},{"key":"139_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology. 2004;126:402\u201313.","journal-title":"Gastroenterology"},{"key":"139_CR7","first-page":"1107","volume":"22","author":"E Dome\u2019nech","year":"2005","unstructured":"Dome\u2019nech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn\u2019s disease after inducing remission with infliximab: how long should patients be treated? AlimentPharmacol Ther. 2005;22:1107\u201313.","journal-title":"AlimentPharmacol Ther"},{"key":"139_CR8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, inmunomoduladors, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940\u201387.","journal-title":"Gastroenterology"},{"key":"139_CR9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-2008-1077445","volume":"40","author":"G Terheggen","year":"2008","unstructured":"Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656\u201363.","journal-title":"Endoscopy"},{"key":"139_CR10","first-page":"15","volume":"16","author":"HJ Freeman","year":"2010","unstructured":"Freeman HJ. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol. 2010;16:15\u201320.","journal-title":"World J Gastroenterol"},{"key":"139_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11547-012-0841-7","volume":"118","author":"L Macarini","year":"2013","unstructured":"Macarini L, Stoppino LP, Centola A, et al. Assessment of activity of Crohn\u2019s disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score. Radiol Med. 2013;118:181\u201395.","journal-title":"Radiol Med"},{"issue":"suppl 170","key":"139_CR12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/00365528909091339","volume":"24","author":"JE Lennard Jones","year":"1989","unstructured":"Lennard Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24 suppl 170:2\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"139_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"key":"139_CR14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/gut.2008.167957","volume":"58","author":"J Rimola","year":"2009","unstructured":"Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn\u2019s disease. Gut. 2009;58:1113\u201320.","journal-title":"Gut"},{"key":"139_CR15","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ibd.21551","volume":"17","author":"J Rimola","year":"2011","unstructured":"Rimola J, Ordas I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn\u2019s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759\u201368.","journal-title":"Inflamm Bowel Dis"},{"key":"139_CR16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"139_CR17","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0016-5085(10)61648-4","volume":"138","author":"M Ferrante","year":"2010","unstructured":"Ferrante M, Noman M, Vermeire S, et al. Evolution of endoscopic activity scores under placebo therapy in Crohn\u2019s disease. Gastroenterology. 2010;138:S358.","journal-title":"Gastroenterology"},{"key":"139_CR18","first-page":"S1097","volume":"132","author":"DN Moskovitz","year":"2007","unstructured":"Moskovitz DN, Daperno M, Van Assche G, et al. Defining and validating cut-offs for the simple endoscopic score for Crohn\u2019s disease. Gastroenterology. 2007;132:S1097.","journal-title":"Gastroenterology"},{"key":"139_CR19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0016-5085(79)90383-4","volume":"77","author":"DH Winship","year":"1979","unstructured":"Winship DH, Summers RW, Singleton JW, et al. National cooperative Crohn\u2019s disease study: study design and conduct of the study. Gastroenterology. 1979;77:829\u201342.","journal-title":"Gastroenterology"},{"key":"139_CR20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","volume":"15","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease. Inflamm Bowel Dis. 2009;15:1295\u2013301.","journal-title":"Inflamm Bowel Dis"},{"key":"139_CR21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","volume":"145","author":"M Ferrante","year":"2013","unstructured":"Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post-hoc analysis of data from SONIC. Gastroenterology. 2013;145:978\u201386.","journal-title":"Gastroenterology"},{"key":"139_CR22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","volume":"98","author":"R Modigliani","year":"1990","unstructured":"Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn\u2019s disease. Evolution on prednisolone. Groupe d\u2019Etude therapeutique des affections inflammatoires digestives. Gastroenterology. 1990;98:811\u20138.","journal-title":"Gastroenterology"},{"key":"139_CR23","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0016-5085(92)91725-J","volume":"102","author":"B Landi","year":"1992","unstructured":"Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn\u2019s disease treatment: a prospective, randomized clinical trial. The groupe d\u2019Etudes therapeutiques des affections inflammatoires digestives. Gastroenterology. 1992;102:1647\u201353.","journal-title":"Gastroenterology"},{"key":"139_CR24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","volume":"35","author":"C Cellier","year":"1994","unstructured":"Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn\u2019s disease. A prospective multicentre study of 121 cases. The groupe d\u2019Etudes therapeutiques des affections inflammatoires digestives. Gut. 1994;35:231\u20135.","journal-title":"Gut"},{"key":"139_CR25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.dld.2012.11.012","volume":"45","author":"A Buisson","year":"2013","unstructured":"Buisson A, Chevaux JB, Hudziak H, et al. Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre. Dig Liver Dis. 2013;45:569\u201372.","journal-title":"Dig Liver Dis"},{"key":"139_CR26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","volume":"17","author":"B Pariente","year":"2011","unstructured":"Pariente B, Cosnes J, Danese S, et al. Development of the Crohn\u2019s disease digestive damage score, the L\u00e9mann score. Inflamm Bowel Dis. 2011;17:1415\u201322.","journal-title":"Inflamm Bowel Dis"},{"key":"139_CR27","first-page":"1","volume":"6736","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;6736:1\u201316.","journal-title":"Lancet"},{"key":"139_CR28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s002619900487","volume":"24","author":"SM Madsen","year":"1999","unstructured":"Madsen SM, Thomsen HS, Schlichting P, et al. Evaluation of treatment response in active Crohn\u2019s disease by low-field magnetic resonance imaging. Abdom Imaging. 1999;24:232\u20139.","journal-title":"Abdom Imaging"},{"key":"139_CR29","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2013.10.055","volume":"146","author":"I Ordas","year":"2014","unstructured":"Ordas I, Rimola J, Rodriguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn\u2019s disease. Gastroenterology. 2014;146:374\u201382.","journal-title":"Gastroenterology"},{"key":"139_CR30","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.crohns.2013.01.011","volume":"7","author":"G Assche Van","year":"2013","unstructured":"Van Assche G, Herrmann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn\u2019s disease. J Crohns Colitis. 2013;7:950\u20137.","journal-title":"J Crohns Colitis"},{"key":"139_CR31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","volume":"23","author":"P Rutgeerts","year":"2006","unstructured":"Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease\u2013seven years on. Aliment Pharmacol Ther. 2006;23:451\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR32","first-page":"1943","volume":"19","author":"JA Tielbeek","year":"2013","unstructured":"Tielbeek JA, Lowenberg M, Bipat S, et al. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn\u2019s disease. Inflamm Bowel Dis. 2013;19:1943\u201350.","journal-title":"Inflamm Bowel Dis"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-016-0139-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T05:23:47Z","timestamp":1567833827000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-016-0139-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1186\/s12880-016-0139-7","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]},"article-number":"37"}}